A Phase 1, Open-Label, Single-Dose, Parallel-Group Study to Assess the Safety, Tolerability, and Pharmacokinetics of TD-1211 Administered Orally to Elderly and Young Healthy Subjects
Latest Information Update: 15 Jan 2021
Price :
$35 *
At a glance
- Drugs Axelopran (Primary)
- Indications Constipation
- Focus Pharmacokinetics
- Sponsors Theravance; Theravance Biopharma
- 23 May 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 01 Mar 2013 Planned End Date changed from 1 Dec 2012 to 1 Mar 2013 as reported by ClinicalTrials.gov.
- 01 Mar 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.